MEDICATION, METHOD OF OBTAINING MEDICATION, AND METHOD OF TREATMENT FOR CORNEA EDEMA AND OTHER EARLY BULLOUS KERATOPATHY MANIFESTATIONS

摘要

FIELD: medicine.;SUBSTANCE: invention concerns ophthalmology and is intended for treatment of cornea edema and other bullous keratopathy manifestations. Medication includes leukocyte suspension of 1200-1500x10³ cells/ml in autological serum, where mononuclears comprise 400-570x10³ cells per 1 ml of suspension. Additionally medication includes cytokines, interleukines, b-FGF, TGF-b2 growth factors, endogenic TLR ligands, including heat shock proteins. Leukocyte suspension is obtained out of patient blood and activated by polyA:polyU TLR ligand complex (Poludan). Method of medication obtainment involves addition of polyA:polyU (Poludan) solution to patient blood sample at the ratio of 200-400 units per ml, cell activation at +18-+41 C° for 4-8 hours, centrifugation at 100-400G acceleration. Medication is injected in anterior eye chamber in amount of 0.5-1.0 ml until complete substitution of anterior chamber fluid by medication, by intracorneal method if required, and additionally activated autological cell suspension in autological serum is injected in amount of 1.0-2.0 ml paralimbally under conjunctiva in combination with antibiotic.;EFFECT: direct effect on damaged cornea endothelium, stopped or reduced cornea edema and other manifestations of early bullous keratopathy, increased visual acuity.;3 cl, 2 ex